Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro successfully implanted the first WATCHMAN FLX Pro Device on April 1. MCH ...
MedStar Heart & Vascular Institute now offers patients with irregular heart rhythm a minimally invasive option to reduce the risk of stroke, as well as enable stopping long-term use of blood thinning ...
REDDING, Calif. — It's called the Watchman. No, not the Sony Watchman from the 80s, but an implant that allows heart patients to throw away their blood thinners and reduce the chances of having a ...
BOSTON, MA—For patients with atrial fibrillation who are undergoing left atrial appendage occlusion (LAAO), the Amplatzer Amulet (Abbott) and the first-generation Watchman 2.5 (Boston Scientific) ...
On Saturday, Boston Scientific Corporation (NYSE:BSX) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device ...
Procedural success and safety outcomes in real-world populations with nonvalvular atrial fibrillation (AF) undergoing left atrial appendage occlusion (LAAO) with the Watchman FLX device (Boston ...
MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...
SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...
Add Yahoo as a preferred source to see more of our stories on Google. Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results